Evidence map›Paper›PMID 41186226›Full record

ArticleAntimicrobial agents and chemotherapy2025

Emergence of co-resistance to imipenem/relebactam and ceftazidime/avibactam in clinical

Yiqi Fu, Yuchao Zhang, Jun Zhao, Jiahong Xie, Haishen Kong, Tingting Yang, Wei Chen, Min Xu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Targeting KPC-ProducingMicroorganisms · 2026
    Article
  2. Article
  3. Phage and endolysin-based inhibition ofFrontiers in cellular and infection microbiology · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Yiqi FuDepartment of Respiratory Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.ORCID 0000-0001-8134-7994
Yuchao ZhangState Key Laboratory for Diagnosis and Treatment of Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Jun ZhaoDepartment of Respiration, Zhejiang Medical & Health Group Hangzhou Hospital, Hangzhou, China.
Jiahong XieDepartment of Food Science and Nutrition, College of Biosystems Engineering and Food Science, Zhejiang University, Hangzhou, China.
Haishen KongState Key Laboratory for Diagnosis and Treatment of Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Tingting YangDepartment of Laboratory Medicine, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Wei ChenDepartment of Food Science and Nutrition, College of Biosystems Engineering and Food Science, Zhejiang University, Hangzhou, China.ORCID 0000-0002-2373-2437
Min XuDepartment of Laboratory Medicine, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.ORCID 0009-0002-2502-9603

Funding

Medical Science and Technology Project of Zhejiang Province 2022KY288National Natural Science Foundation of China 82202585
6 · The paper itself

Abstract

Two episodes of imipenem/relebactam and ceftazidime/avibactam co-resistant

Indexed as

Anti-Bacterial AgentsAzabicyclo Compoundsbeta-LactamasesCeftazidimeDrug Resistance, Multiple, BacterialImipenemKlebsiella pneumoniaeDrug CombinationsHumansKlebsiella InfectionsMicrobial Sensitivity TestsPlasmidsAnti-Bacterial Agentsavibactam, ceftazidime drug combinationAzabicyclo Compoundsbeta-lactamase KPC-2beta-lactamase KPC-2, Klebsiella pneumoniaebeta-LactamasesCeftazidimeDrug CombinationsImipenemrelebactamceftazidime/avibactamCTX-Mimipenem/relebactamKlebsiella pneumoniaeKPC

Identifiers

PMID41186226
PMCPMC12691654

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.